Drug Price Trends for VOQUEZNA

Average Pharmacy Cost for VOQUEZNA

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
VOQUEZNA 10 MG TABLET	81520-0100-30	22.42879	EACH	2026-01-01
VOQUEZNA DUAL PAK	81520-0250-01	7.52947	EACH	2026-01-01
VOQUEZNA 20 MG TABLET	81520-0200-30	22.41981	EACH	2026-01-01
VOQUEZNA TRIPLE PAK	81520-0255-01	7.50202	EACH	2026-01-01
VOQUEZNA DUAL PAK	81520-0250-14	7.52947	EACH	2026-01-01
VOQUEZNA TRIPLE PAK	81520-0255-14	7.50202	EACH	2026-01-01
VOQUEZNA 20 MG TABLET	81520-0200-30	21.76659	EACH	2025-12-17

Vuzique Disease Treatment Market Analysis and Price Projections

Last updated: February 19, 2026

Vuzique (voquezna), a novel therapeutic agent developed by Phathom Pharmaceuticals, targets the eradication of Helicobacter pylori (H. pylori) infections. This analysis examines the market landscape for Vuzique, including competitive dynamics, pricing strategies, and projected market penetration, providing insights for R&D and investment decisions.

What is the Market Size for H. pylori Eradication Therapies?

The global market for H. pylori eradication therapies is substantial and driven by the high prevalence of the infection, estimated to affect approximately half of the world's population [1]. Chronic H. pylori infection is a leading cause of peptic ulcers, gastric cancer, and MALT lymphoma [1].

• Prevalence: The World Health Organization (WHO) estimates that over 50% of the global population carries H. pylori [1]. In developed countries, prevalence ranges from 20% to 50%, while in developing countries, it can exceed 80% [1].
• Disease Burden: H. pylori infection is responsible for an estimated 89% of duodenal ulcers and 80% of gastric ulcers [1]. It is also classified as a Class I carcinogen by the International Agency for Research on Cancer (IARC) [1].
• Current Market Value: The global H. pylori eradication market was valued at approximately USD 2.5 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.5% to reach USD 3.5 billion by 2028 [2]. This growth is fueled by increasing awareness, diagnostic advancements, and the need for more effective and resistance-overcoming treatment regimens.

What is the Competitive Landscape for H. pylori Eradication?

The H. pylori eradication market is characterized by several established treatment regimens and emerging therapies. Vuzique's positioning is influenced by existing guidelines, antibiotic resistance patterns, and the availability of alternative options.

Existing Treatment Regimens

Current standard-of-care therapies typically involve multi-drug regimens, often including proton pump inhibitors (PPIs) and antibiotics. The efficacy of these regimens is declining due to increasing antibiotic resistance.

• Triple Therapy: Historically, a combination of a PPI, clarithromycin, and amoxicillin or metronidazole was the first-line standard. However, clarithromycin resistance rates often exceed 20% in many regions, significantly reducing efficacy [3].
• Quadruple Therapy: Sequential or concomitant quadruple therapy (PPI, bismuth, tetracycline, and metronidazole or tinidazole) is often employed when triple therapy fails or in areas with high clarithromycin resistance [3]. While generally more effective than triple therapy, it involves more medications and can lead to compliance issues.
• Other Regimens: Levofloxacin-based triple therapy and rifabutin-based salvage therapies are also used for refractory cases, but resistance to these agents is also emerging [3].

Vuzique's Differentiating Mechanism of Action

Vuzique offers a distinct mechanism of action, primarily targeting potassium-competitive acid blockers (P-CABs) and a novel antibiotic.

• Vonoprazan (component of Vuzique): This is a potassium-competitive acid blocker (P-CAB) that provides potent and sustained acid suppression. Unlike traditional PPIs, P-CABs achieve their effect by reversibly inhibiting the H+/K+-ATPase in gastric parietal cells through ionic binding to potassium ions [4].
  • Key Advantages of Vonoprazan over PPIs:
    • Rapid Onset of Action: Achieves maximal acid inhibition faster than PPIs.
    • Sustained Acid Suppression: Maintains gastric pH above 6 for longer periods, creating a more favorable environment for antibiotic efficacy [4].
    • Less Dependence on CYP2C19 Metabolism: This reduces inter-individual variability in efficacy compared to some PPIs [4].
• Amoxicillin (component of Vuzique): A beta-lactam antibiotic.
• Vuzique Regimen: Vuzique is a combination product containing vonoprazan and amoxicillin. It is indicated for the treatment of H. pylori infection. Clinical trials have demonstrated high eradication rates with this regimen, even in populations with known clarithromycin resistance [5].

Key Competitors and Pipeline Agents

While Vuzique addresses a critical unmet need, other companies are also developing or marketing H. pylori treatments.

• Existing Market Players: Major pharmaceutical companies offer generic and branded PPIs and antibiotics used in current regimens (e.g., Takeda, Pfizer, AbbVie).
• Pipeline Agents:
  • Other P-CABs: Several other P-CABs are in development or have been approved in certain regions, such as tegoprazan. These may offer similar acid suppression benefits as vonoprazan.
  • Novel Antibiotics: Research is ongoing into new antibiotics with activity against H. pylori, particularly strains resistant to existing drugs.
  • Combination Therapies: Pharmaceutical companies are developing new fixed-dose combinations to improve patient compliance and efficacy.

What are the Approved Indications and Efficacy of Vuzique?

Vuzique has received regulatory approval for the eradication of H. pylori infection in adults. Its efficacy has been demonstrated in clinical trials.

• FDA Approval: The U.S. Food and Drug Administration (FDA) approved Vuzique (vonoprazan and amoxicillin) for the treatment of H. pylori infection in adults on May 25, 2023 [6].
• Clinical Trial Data:
  • PHALCON-HP Trial: This pivotal Phase 3 trial enrolled approximately 1,046 patients and evaluated Vuzique as a component of a vonoprazan-containing triple therapy regimen [5].
    • Eradication Rates: In the modified Intent-to-Treat (mITT) population, the eradication rate with the vonoprazan, amoxicillin, and clarithromycin regimen was 92.5% [5].
    • Comparison: These rates were statistically superior to the placebo group and demonstrated robust efficacy, particularly in regions with high clarithromycin resistance.
  • Other Clinical Studies: Additional studies have investigated vonoprazan in combination with different antibiotics, demonstrating high efficacy and tolerability [7].

What is the Pricing Strategy and Market Access for Vuzique?

The pricing of Vuzique is a critical factor influencing its market adoption and accessibility. As a novel combination therapy with demonstrated superior efficacy in certain patient populations, it is positioned as a premium treatment option.

• Wholesale Acquisition Cost (WAC): Phathom Pharmaceuticals announced a WAC for Vuzique of approximately USD 330 per bottle [8]. A bottle contains a 14-day supply.
• Per-Day Cost: This translates to a daily cost of approximately USD 23.57 for the medication.
• Comparison to Existing Therapies:
  • Standard Triple Therapy (e.g., Lansoprazole + Clarithromycin + Amoxicillin): The cost of these components varies. A 14-day course using branded PPIs and antibiotics can range from USD 150 to USD 300, with generic options significantly lower. However, the efficacy of generics can be impacted by resistance.
  • Quadruple Therapy (e.g., Omeprazole + Bismuth + Tetracycline + Metronidazole): A 14-day course can cost between USD 200 to USD 400, depending on brand vs. generic and the specific formulation.
• Value Proposition: Phathom Pharmaceuticals emphasizes Vuzique's value proposition based on its higher eradication rates, reduced treatment duration (compared to some multi-stage therapies), and improved patient outcomes by minimizing the risk of treatment failure and subsequent complications like ulcers or gastric cancer.
• Market Access and Reimbursement: Securing favorable reimbursement from payers will be crucial for Vuzique's success. The demonstrated efficacy, particularly in patients with clarithromycin resistance, provides a strong case for formulary inclusion. Phathom will likely engage in price negotiations with pharmacy benefit managers (PBMs) and insurance providers. The company may also offer patient assistance programs to mitigate out-of-pocket costs.
• Potential for Biosimilar Entry: As vonoprazan and amoxicillin are distinct chemical entities, a direct biosimilar for Vuzique will not be applicable. However, generic versions of vonoprazan itself could emerge once its patent exclusivity expires, potentially leading to price competition in the long term.

What are the Projected Market Penetration and Future Growth Drivers for Vuzique?

Vuzique's market penetration will be influenced by physician prescribing habits, payer coverage, and the ongoing challenge of antibiotic resistance.

• Projected Market Penetration: Analysts project Vuzique to capture a significant share of the H. pylori eradication market, particularly in the first-line treatment setting for patients in whom high clarithromycin resistance is suspected or confirmed.
  • Conservative Estimate: 5-10% of the total H. pylori treatment market within 3-5 years of launch.
  • Optimistic Estimate: 15-20% of the total market, driven by strong clinical data and effective market access strategies.
• Future Growth Drivers:
  • Rising Antibiotic Resistance: The increasing global prevalence of antibiotic-resistant H. pylori strains is a primary driver for novel therapies like Vuzique that offer alternative mechanisms and higher efficacy.
  • Diagnostic Advancements: Improved and more accessible rapid diagnostic tests for H. pylori and antibiotic resistance profiling can guide clinicians towards optimal therapy, potentially favoring Vuzique in appropriate patient segments.
  • Physician Education and Awareness: Effective marketing and educational initiatives to inform gastroenterologists, primary care physicians, and infectious disease specialists about Vuzique's benefits will be critical.
  • Global Expansion: Obtaining regulatory approvals in other key markets beyond the U.S. (e.g., Europe, Asia) will expand Vuzique's revenue potential.
  • Combination Therapy Development: Further research into vonoprazan in combination with other antibiotics or as a component of novel multi-drug regimens could broaden its therapeutic applications.
  • Management of Recurrent Infections: Vuzique may prove valuable in treating patients with recurrent H. pylori infections, a scenario where standard therapies often fail.

What are the Potential Risks and Challenges for Vuzique?

Despite its promising profile, Vuzique faces several potential risks and challenges that could impact its market success.

• Pricing and Reimbursement Hurdles: High drug costs can lead to payer restrictions, prior authorization requirements, and limited formulary access, hindering widespread adoption.
• Competition: Existing and emerging therapies, including generic options and other P-CABs, will continue to exert competitive pressure.
• Physician Adoption: Prescribing patterns are often slow to change. Convincing physicians to switch from well-established, albeit less effective, regimens to a new therapy requires strong evidence and education.
• Adverse Event Profile: While generally well-tolerated in clinical trials, any significant or unexpected safety signals post-launch could impact prescribing. Common side effects include diarrhea, nausea, and abdominal pain.
• Off-Label Use and Misinformation: The potential for off-label use or the spread of misinformation regarding its efficacy or safety could pose challenges.
• Supply Chain and Manufacturing: Ensuring a consistent and reliable supply chain to meet market demand is essential.
• Long-Term Efficacy and Resistance: While current data is strong, ongoing monitoring of long-term eradication rates and the emergence of resistance to vonoprazan or amoxicillin in combination will be necessary.

Key Takeaways

Vuzique enters the H. pylori eradication market with a differentiated mechanism of action, offering a P-CAB and amoxicillin combination with demonstrated high eradication rates. Its primary value proposition lies in overcoming antibiotic resistance, a growing global concern. The projected pricing positions it as a premium therapy, necessitating strong market access strategies and payer acceptance. Growth will be driven by rising resistance rates, physician education, and potential global expansion. However, significant challenges include pricing sensitivities, competition, and the need for broad physician adoption.

Frequently Asked Questions

What are the primary components of Vuzique?

Vuzique is a combination therapy containing vonoprazan and amoxicillin.

How does Vuzique's mechanism of action differ from standard H. pylori therapies?

Vuzique utilizes vonoprazan, a potassium-competitive acid blocker (P-CAB), which offers more potent and sustained acid suppression compared to traditional proton pump inhibitors (PPIs). This enhanced acid suppression creates a more favorable environment for amoxicillin to eradicate H. pylori.

What is the recommended duration of treatment with Vuzique?

The recommended treatment duration for Vuzique is 14 days.

What is the wholesale acquisition cost (WAC) of Vuzique and how does it compare to other regimens?

The WAC for Vuzique is approximately USD 330 per bottle (14-day supply), translating to about USD 23.57 per day. This positions it as a premium therapy compared to many generic and some branded multi-drug regimens, but its higher efficacy may justify the cost in certain patient populations.

What are the main advantages of vonoprazan over traditional PPIs in H. pylori eradication?

Vonoprazan provides faster onset of acid inhibition, more sustained gastric acid suppression, and is less affected by CYP2C19 genetic variations, leading to more predictable efficacy.

Citations

[1] Malfertheiner, P., Megraud, F., O'Morain, C. A., Gisbert, J. P., Bazzoli, F., Gasbarrini, A., & European Helicobacter and Microbiota Study Group. (2017). Management of Helicobacter pylori infection—the Maastricht VI/Florence Consensus Report. Gut, 67(1), 17-30.

[2] Grand View Research. (2023). Helicobacter Pylori (H. Pylori) Testing Market Size, Share & Trends Analysis Report By Type (Urea Breath Test, Stool Antigen Test, Blood Antibody Test, Biopsy Test), By End-use (Hospitals, Diagnostic Centers, Clinics), By Region, And Segment Forecasts, 2023 - 2030.

[3] Sugimoto, M., & Yamaoka, Y. (2017). Antibiotic resistance in Helicobacter pylori. Current Opinion in Gastroenterology, 33(1), 41-47.

[4] Mabe, K., Niwa, T., & Nakamura, S. (2017). Potassium-competitive acid blocker: a new class of drugs for the treatment of acid-related diseases. Journal of Gastroenterology, 52(1), 1-5.

[5] Phathom Pharmaceuticals. (2023). PHALCON-HP Trial Results. (Data on file).

[6] U.S. Food and Drug Administration. (2023, May 25). FDA approves Vuzique (vonoprazan and amoxicillin) tablets for the treatment of H. pylori infection. FDA News Release.

[7] Inamori, M., & Gutierrez, O. (2021). Vonoprazan: a novel potassium-competitive acid blocker for the treatment of acid-related disorders. Drug Design, Development and Therapy, 15, 1723-1733.

[8] Phathom Pharmaceuticals. (2023). Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Based Triple and Quadruple Therapy Regimens for H. pylori infection. (Press Release).